Coverage of clinical trial results presented across a range of solid tumor cancers, including breast, ovarian, colorectal, and non-small cell lung cancer, among other types; as well as important findings in genomic testing.
Brittany Lovely
Advertisement
Brittany Lovely is a managing editor for the OncologyLive® print publication and editor of the Miami Breast Cancer Conference® and Chemotherapy Foundation Symposium® dailies.
Articles by Brittany Lovely
Enhanced antitumor activity was seen with the addition of the PARP inhibitor olaparib to the radioligand lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer.
Advertisement
Latest Updated Articles
ASCO 2023: Solid TumorsJuly 31st 2023
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”
3
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
4
How MCOs Should Be Preparing for the OBBBA's Medicaid Cuts: David Brueggeman, MBA
5